Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Crown Laboratories Completes Acquisition of Revance Therapeutics - Happi

What are you searching for?

Sign in
Financial News

Crown Laboratories Completes Acquisition of Revance Therapeutics

The entities first announced the merger agreement – a deal valued at $924 million – in August 2024.

Author Image

By: Lianna Albrizio

Associate Editor, Happi

Crown Laboratories, Inc. has successfully closed its acquisition of biotechnology company Revance Therapeutics, Inc.

The entities first announced the merger agreement – a deal valued at $924 million – in August 2024.

Jeff Bedard, founder and CEO of Crown, previously said the combined entities would be afforded the opportunity to create a comprehensive portfolio of high-growth products for all stages of life, and that as a unit, would be committed to investing in education, training and practice support for aesthetics providers across the US.

Based in Nashville, TN, Revance is a Nasdaq-traded company whose portfolio includes Daxxify (DaxibotulinumtoxinA-lanm), an FDA -pproved injectable peptide formulated neuromodulator that competes with Botox, and the RHA Collection, an FDA approved hyaluronic acid filler line.

Revance’s common stock will be delisted from the NASDAQ Global Select Market and deregistered under the Securities Exchange Act of 1934, as amended.

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Add Happi as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Happi Newsletters

Topics